

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM425580

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Cancer Genetics, Inc.		03/22/2017	Corporation: DELAWARE
RECEIVING PARTY DATA			
Name:	Partners for Growth V, L.P.		
Street Address:	1660 TIBURON BLVD.		
Internal Address:	SUITE D		
City:	TIBURON		
State/Country:	CALIFORNIA		
Postal Code:	94920		
Entity Type:	Limited Partnership: DELAWARE		
PROPERTY NUMBERS Total: 12			
Property Type	Number	Word Mark	
Registration Number:	3993858	CGI	
Registration Number:	4212523	CLL COMPLETE	
Registration Number:	3964780	EMPOWERING PERSONALIZED CANCER TREATMENT	
Registration Number:	4158255	FHACTION	
Registration Number:	4084491	MATBA	
Registration Number:	4511347	SELECT ONE	
Registration Number:	5141000	FOCUS::NGS	
Registration Number:	4514927	UROGENRA	
Registration Number:	3970898	BECAUSE EVERYONE HAS A DIFFERENT RESPON	
Registration Number:	3886876	KRAS IS ONLY HALF THE EQUATION	
Registration Number:	4376661	RESPONSEDX	
Registration Number:	3811603	THE RIGHT THERAPY FOR EACH PATIENT THE F	
CORRESPONDENCE DATA			
Fax Number:	4157385371		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	415-381-3283		
Email:	ben@greenspan-law.com		

OP \$315.00 3993858

Correspondent Name: Benjamin Greenspan
Address Line 1: 620 Laguna Rd
Address Line 4: Mill Valley, CALIFORNIA 94941

NAME OF SUBMITTER: Benjamin Greenspan

SIGNATURE: /bg/

DATE SIGNED: 04/29/2017

Total Attachments: 3

source=Item 09 - USPTO Trademark Notice for filing#page1.tif

source=Item 09 - USPTO Trademark Notice for filing#page2.tif

source=Item 09 - USPTO Trademark Notice for filing#page3.tif

TRADEMARK COLLATERAL AGREEMENT AND NOTICE

This Trademark Collateral Agreement and Notice dated as of March 22 2017 ("Trademark Agreement"), is between Cancer Genetics, Inc., a Delaware corporation with its principal place of business at 201 Route 17 N., 2nd Floor, Rutherford, NJ 07070 ("Assignor") and Partners for Growth IV, L.P., 1660 Tiburon Blvd., Suite D, Tiburon, California 94920 ("Assignee") pursuant to a Loan and Security Agreement and an Intellectual Property Security Agreement of even date herewith by and among Assignor, Assignee and a Subsidiary of Assignee (the "IP Security Agreement") and pursuant to certain other loan documents referenced therein (collectively, the "Loan Documents").

WHEREAS, Assignor is the owner of certain trademarks, including all federal applications and/or registrations therefor, together with the goodwill of the business connected with the use of and symbolized thereby, as listed on Exhibit I hereto (the "Marks"); and

WHEREAS, Assignee has agreed to extend certain credit to Assignor on condition that the Assignor pledge and grant to Assignee as collateral for the Obligations (as defined in the Loan Documents) a security interest and lien in and to the Marks and all proceeds thereof and all other related claims and rights as more fully described in the IP Security Agreement in favor of the Assignee, by and among Assignor and Assignee;

NOW THEREFORE, for good and valuable consideration, as security for the due and timely payment and performance of the Obligations, Assignor hereby pledges and grants to Assignee a security interest and lien in and to the Marks and all proceeds thereof and gives notice of such security interest and the existence of such Security Agreement providing therefor.

Executed as of the date first above written.

Assignor:

Cancer Genetics, Inc.

By 

Chief Executive Officer

By _____

Secretary

Assignee:

PARTNERS FOR GROWTH IV, L.P.

By _____

Name: _____

Title: Manager, Partners for Growth IV, LLC
Its General Partner

TRADEMARK COLLATERAL AGREEMENT AND NOTICE

This Trademark Collateral Agreement and Notice dated as of March 22, 2017 ("Trademark Agreement"), is between Cancer Genetics, Inc., a Delaware corporation with its principal place of business at 201 Route 17 N., 2nd Floor, Rutherford, NJ 07070 ("Assignor") and Partners for Growth IV, L.P., 1660 Tiburon Blvd., Suite D, Tiburon, California 94920 ("Assignee") pursuant to a Loan and Security Agreement and an Intellectual Property Security Agreement of even date herewith by and among Assignor, Assignee and a Subsidiary of Assignee (the "IP Security Agreement") and pursuant to certain other loan documents referenced therein (collectively, the "Loan Documents").

WHEREAS, Assignor is the owner of certain trademarks, including all federal applications and/or registrations therefor, together with the goodwill of the business connected with the use of and symbolized thereby, as listed on Exhibit 1 hereto (the "Marks"); and

WHEREAS, Assignee has agreed to extend certain credit to Assignor on condition that the Assignor pledge and grant to Assignee as collateral for the Obligations (as defined in the Loan Documents) a security interest and lien in and to the Marks and all proceeds thereof and all other related claims and rights as more fully described in the IP Security Agreement in favor of the Assignee, by and among Assignor and Assignee;

NOW THEREFORE, for good and valuable consideration, as security for the due and timely payment and performance of the Obligations, Assignor hereby pledges and grants to Assignee a security interest and lien in and to the Marks and all proceeds thereof and gives notice of such security interest and the existence of such Security Agreement providing therefor.

Executed as of the date first above written.

Assignor:

Cancer Genetics, Inc.

By _____
Chief Executive Officer

By _____
Secretary

Assignee:

PARTNERS FOR GROWTH IV, L.P.

By 
Name: Philip Lawson

Title: Manager, Partners for Growth IV, LLC
Its General Partner

**EXHIBIT 1
Cancer Genetics, Inc.**

Trademark Schedule

Serial Number - Registration Number	Date	Mark	Owner
3,993,858	2011	CGI	Cancer Genetics, Inc.
4,212,523	2012	CLL Complete	Cancer Genetics, Inc.
3,964,780	2011	Empowering Personalized Cancer Treatment	Cancer Genetics, Inc.
4,158,255	2012	FHACT	Cancer Genetics, Inc.
4,084,491	2012	MATBA	Cancer Genetics, Inc.
4,511,347	2014	Select One	Cancer Genetics, Inc.
5,141,000	2017	Focus: NGS	Cancer Genetics, Inc.
4,514,927	2014	UROGENRA	Cancer Genetics, Inc.
3,970,898	2011	Because Everyone has a Different Response	Response Genetics, Inc. acquired by CGI
3,886,876	2010	KRAS is only half the equation	Response Genetics, Inc. acquired by CGI
4,376,661	2013	ResponseDX	Response Genetics, Inc. acquired by CGI
3,811,603	2010	The right therapy for each patient the first time	Response Genetics, Inc. acquired by CGI